Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. We have significant market opportunities with a first-in-class molecule that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes.

In addition, we have a value-driven, fully out-licensed partnership with MedImmune for a second core program.

Genaera is committed to directing resources to its core program and the aggressive clinical development of its key assets to build stockholder value.

Management Team

• John L. Armstrong, Jr.
• Michael Gast, M.D., Ph.D.
• Henry R. Wolfe, Ph.D.
• Leanne M. Kelly, CPA

Recent News:

• Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting

  July 14th, 2008

• Genaera Corporation Elects Paul K. Wotton to Board of Directors

  June 30th, 2008

• Genaera Corporation to Present at BIO Business Forum

  June 12th, 2008

• Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association

  June 9th, 2008

Upcoming Events:

• American Diabetes Association Meeting
  New Orleans, LA

  June 6th, 2008 -- June 10th, 2008